Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

18.90USD
4:00pm EDT
Change (% chg)

$0.59 (+3.22%)
Prev Close
$18.31
Open
$18.33
Day's High
$19.06
Day's Low
$18.30
Volume
482,268
Avg. Vol
362,555
52-wk High
$19.06
52-wk Low
$11.47

IRWD.OQ

Chart for IRWD.OQ

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $2,721.17
Shares Outstanding(Mil.): 148.62
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -0.83 -- --
ROI: -21.07 2.25 -5.72
ROE: -200.56 0.17 -5.10

BRIEF-Ironwood Pharmaceuticals reports Q1 loss per share of $0.36

* Ironwood pharmaceuticals provides first quarter 2017 investor update

May 08 2017

BRIEF-Ironwood pharmaceuticals qtrly loss per share $0.09

* Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million.

Feb 21 2017

BRIEF-Ironwood Pharmaceuticals and Allergan entered into amendment to license agreement, dated April 30, 2009

* Ironwood Pharmaceuticals Inc - Co and Allergan Pharmaceuticals International Ltd. entered into amendment to license agreement, dated April 30, 2009

Feb 01 2017

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

Jan 29 2017

More From Around the Web

Earnings vs. Estimates